Anticoagulant Therapy for Acute Pancreatitis-Related Splanchnic Vein Thrombosis

Anticoagulant Therapy for Acute Pancreatitis-Related Splanchnic Vein Thrombosis

2024.03.12
The "Hepatology Digest - Liver Vascular Disease Column" is an academic column initiated by Dr. Qixing Shun from the Department of Gastroenterology, Northern Theater General Hospital, in response to the invitation of the editorial department of "Hepatology Digest". It regularly collects and organizes research progress in the field of hepatic vascular diseases. Every two weeks (Wednesday), an important literature is selected for in-depth discussion, aiming to help readers understand the rationale behind clinical research, inspiring clinical and scientific thinking.
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial

Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial

2024.03.12
In July 2022, a study led by Professor Feng Xue et al. was published in the international academic journal ——Lancet Haematol. The title of the study is "Safety and activity of an engineered, liver-tropic…
Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

Revolutionizing Multiple Myeloma Treatment: FCRL5-Directed CAR-T Cells Enhanced with IL-15 Show Promising Antitumor Activity

2024.03.08
In January 2024, a study led by Professor Ting Niu from West China Hospital, Sichuan University was published in the international academic journal ——Signal Transduction And Targeted Therapy (IF=38.104). The title of the study is "Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma". This study sheds light on the promising potential of FCRL5-directed CAR-T cell therapy in the treatment of multiple myeloma (MM).